Fenofibrate/pravastatin

Drug Profile

Fenofibrate/pravastatin

Alternative Names: Duochol; PravaFen; Pravafenix

Latest Information Update: 07 May 2015

Price : $50

At a glance

  • Originator Galephar Pharmaceutical Research; SMB
  • Developer Shionogi Pharma; SMB
  • Class Antihyperlipidaemics; Butyric acids; Naphthalenes; Propionates
  • Mechanism of Action HMG-CoA reductase inhibitors; Peroxisome proliferator-activated receptor alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Hyperlipidaemia

Most Recent Events

  • 07 Apr 2015 No recent reports of development identified - Preregistration for Hyperlipidaemia in USA (PO)
  • 01 May 2014 Yooyoung Pharmaceutical initiates enrolment in a phase III trial for Hyperlipidaemia in South Korea (NCT02166593)
  • 01 Sep 2013 Fenofibrate/pravastatin licensed to undisclosed companies in Brazil, Colombia, South Africa, South East Asia and the Middle East
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top